Scientists at the National Research Center for Epidemiology and…
Scientists at the National Research Center for Epidemiology and Microbiology named after Gamaleya in Russia have developed a prototype of an oncological vaccine targeting non-small cell lung cancer, the most common type of cancer, primarily affecting smokers. The vaccine is based on the same scheme used for the personalized mRNA vaccine 'Neooncovak' against melanoma.
Consensus
- Scientists at the National Research Center for Epidemiology and Mikrobiology named after Gamaleya developed a prototype of an oncological vaccine against non-small cell lung cancer.
- The prototype is based on the same scheme used in the development of the personalized mRNA vaccine 'Neooncovak'.
- Non-small cell lung cancer is the most common type of cancer and primarily affects smokers.
- The vaccine is still in the prototype stage and requires further clinical trials to confirm safety and effectiveness.
- Work on oncological vaccines for other types of cancer is ongoing at the center.
Points of divergence
- The first patient who received the 'Neooncovak' vaccine was a 60-year-old man from Kursk Oblast with skin cancer, and he received the vaccine on April 1. — vesti
- The patient who received 'Neooncovak' showed a good immune response and is producing necessary cytokines that help destroy tumor cells. — vesti
- The vaccine is considered a potential breakthrough in therapy, especially for patients at high risk of recurrence. — riamo
- The vaccine is being prepared for further testing and must go through several stages of clinical trials before registration. — riamo
- The first patient who received 'Neooncovak' feels well and continues treatment, with his body producing compounds that help the immune system fight tumor cells and metastases. — vm
- The method of vaccine administration depends on the stage of melanoma: it is injected into the tumor in early stages and into the bloodstream when metastases are present. — vm
Coverage (4 sources)
- In Russia, a prototype vaccine for the most common type of cancer has been created — Вести
- In Russia created a prototype of a vaccine against lung cancer for smokers — РИАМО
- Center Gamalei created prototype of oncovaccine against non-small cell lung cancer — Вечерняя Москва
- Center Gamaleya developed prototype of oncovaccine against non-small cell lung cancer, reported TASS Ginzburg. — ТАСС (Telegram)
Key entities
- Alexander Ginzburg
- TASS
- Russia
- Gamaleya Center
- Moscow
- Ministry of Health
- N. F. Gamaleya National Research Center
- Employees of the N.F. Gamaleya National Research Center for Epidemiology and Microbiology
- National Research Center for Epidemiology and Microbiology (NtCEM) named after G. Gamaleya